Trade: FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?
Resolution criteria on PolyGram: As of market creation, the FDA's expected decision date for the specified application is May 18, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Daiichi Sankyo & AstraZeneca's Enhertu as a treatment for neoadjuvant treatment of adult patients with HER2-positive breast cancer by June 1, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA…
PolyGram is an on-chain prediction market where you trade YES or NO outcome shares with real USDC on Polygon. For this market, buy YES if you believe the event will happen, or NO if you think it won't. Your maximum loss is your stake — winning shares pay $1.00 each at resolution. Unlike sportsbooks, there is no house edge: prices are set by supply and demand from other traders and reflect the crowd's real-time probability.
- Liquidity
- $1K
- Total Volume
- $687
- 24h Volume
- $68
- Open Interest
- $292
Market outcomes
| FDA approves Daiichi Sankyo & AstraZeneca's Enhertu? | 79% YES | 21% NO |
Market context
Daiichi Sankyo and AstraZeneca are seeking FDA approval for Enhertu (fam-trastuzumab deruxtecan-nxki) as a neoadjuvant treatment for HER2-positive breast cancer, with the agency's decision expected by 18 May 2026. The 80% implied probability on Polymarket's order book reflects confidence in approval, though the settlement window extends to 1 June to account for potential administrative delays beyond the target date.
The current pricing aligns with historical approval rates for HER2-directed therapies in breast cancer, where regulatory success has been relatively robust. Enhertu already holds FDA approval for metastatic HER2-positive breast cancer and gastric cancer, establishing a known safety and efficacy profile. The neoadjuvant indication represents an extension into earlier disease stages, where efficacy data from Phase II/III trials typically determines approval likelihood. Similar pathway extensions for established oncology agents have succeeded at comparable or higher rates, though the specific patient population and efficacy thresholds set by the FDA remain material variables.
Traders should monitor FDA communications regarding any Refuse to File determinations or requests for additional data, which would signal approval delays. The company's recent earnings calls and regulatory updates provide insight into submission completeness and any outstanding agency questions. Patent and competitive landscape shifts—particularly regarding other HER2-targeting agents in neoadjuvant settings—could influence the agency's comparative assessment. Any material safety signals or manufacturing concerns raised during review would represent downside catalysts to the current probability estimate.
Wikipedia Context
-
Food and Drug AdministrationThe Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services (HHS). The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (m
How this market resolves
Resolution is handled by the UMA optimistic oracle on Polygon. A proposer submits the outcome, a two-hour dispute window opens, and if no one stakes a counter-claim the payout is final. Contested outcomes escalate to UMA token-holder voting. Payouts clear in USDC to the winning side.
How to trade this market step by step
The mechanics for trading "FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?" are the same as any other PolyGram event contract. Each YES share resolves to $1 if the event happens, or $0 if it doesn't. The current price between 0¢ and 100¢ is the market's probability estimate, set live by the order book.
- Sign in on polygram.ink with your email — no full KYC under $1,500 lifetime trading volume.
- Deposit USDC on Polygon (lowest fees, ~$0.01 per transaction) or Ethereum. Funds credit after 12 confirmations.
- Pick a side. Buy YES if you believe the event will happen; buy NO if you think it won't. The current YES price reflects the market's collective probability.
- Size your position. If you stake 100 USDC at 79% YES, you'll receive shares that pay $127 if YES resolves true — a 27% gross return. If NO resolves, your shares are worth $0.
- Set risk controls (optional). Stop-loss, take-profit, and limit-order types all supported. Use the trade ticket's slippage box to cap your maximum entry price.
- Wait for resolution. When the event resolves on-chain via the UMA optimistic oracle, the winning side settles to 100¢ automatically and USDC hits your balance within seconds. Withdrawable to any wallet you control.
How active is this market?
$687 in lifetime turnover and $1K of resting liquidity puts this market in the below the median by volume for drug contracts on PolyGram. Order-book depth is thin — large orders may need to be split across the book or executed as limit orders.
Last 24 hours alone saw $68 in turnover, well above the lifetime daily-average for this market — a clear sign of news catalysing trader activity right now.
The market has been open for under a month — fresh enough that information asymmetry remains a real factor.
Higher-volume markets tend to have tighter spreads and faster price discovery — meaning the displayed YES/NO percentages are more likely to reflect the true crowd-implied probability rather than a single trader's directional view.
Key terms
- YES / NO share
- A binary outcome token that pays $1.00 if the underlying claim resolves true (YES) or false (NO), and $0 otherwise. The market price between 0¢ and 100¢ is the implied probability.
- CLOB
- Central limit order book. The matching engine that pairs YES buyers with NO buyers (effectively the same trade). Polymarket's CLOB on Polygon executes trades on-chain via the conditional-tokens framework.
- Liquidity
- USDC capital sitting in resting limit orders inside the order book. Deeper liquidity means smaller slippage on large trades and a tighter bid-ask spread.
- UMA optimistic oracle
- The on-chain dispute system that settles each Polymarket market. A proposer submits the outcome, a two-hour challenge window opens, and unchallenged proposals finalise the resolution.
- Slippage
- The difference between the displayed mid-price and your fill price. Affects market orders most; limit orders avoid slippage but may take time to fill.
- Conditional token
- ERC-1155 outcome share issued by Gnosis Conditional Tokens on Polygon. The token type that resolves to $1.00 or $0.00 at settlement.
Frequently asked questions
What is the current probability for "FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?"?
As of today, traders on Polymarket price this outcome at 79%. The number updates continuously as the order book clears. PolyGram mirrors the same live odds with locale-aware formatting and USDC settlement.
How does this market resolve?
Resolution is handled by the UMA optimistic oracle on Polygon. A proposer submits the outcome, a 2-hour dispute window opens, and if uncontested the payout is final. Contested outcomes escalate to UMA token holders.
When does this market close?
This prediction market is scheduled to close on 18 May 2026. After the resolving event occurs, settlement typically clears within 24 hours once the UMA optimistic oracle confirms the outcome. All payouts are in USDC on the Polygon network.
How can I trade on "FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?"?
To trade on this prediction market, create a free PolyGram account at polygram.ink, deposit USDC via Polygon, and place a YES or NO order on the outcome you believe in. You can learn more on our how-it-works page. Your maximum loss is limited to your stake — there is no leverage or margin.
What happens when the market resolves?
When the outcome is determined, winning YES shares pay out $1.00 each in USDC, while losing shares pay $0. Settlement is handled by the UMA optimistic oracle on Polygon — a proposer submits the result, a two-hour dispute window opens, and if uncontested, payouts are distributed automatically. You can withdraw your winnings to any Polygon wallet.
Risk and regulatory note
Prediction-market positions can lose 100% of staked capital. Outcomes are uncertain by definition — historical accuracy of crowd-implied probabilities is high in aggregate but not for any single market. PolyGram does not provide investment advice. Trade only with capital you can afford to lose.
Regulatory status varies by jurisdiction. Germany, the United States, and most EU countries treat Polymarket-style event contracts under one of three frameworks: financial derivative, gambling product, or unregulated novel asset. Consult local counsel before trading.
Related prediction markets
Explore more prediction market odds and trading opportunities on PolyGram: